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Systemic Markers of Inflammation and Cognitive Decline
in Old Age
Miranda T. Schram, PhD,w Sjoerd M. Euser, MSc,w Anton J. M. de Craen, PhD,
Jacqueline C. Witteman, PhD,w Marijke Fro¨lich, PhD, Albert Hofman, MD, PhD,w
Jelle Jolles, MD, PhD,z Monique M. B. Breteler, MD, PhD,w and Rudi G. J. Westendorp, MD, PhD
OBJECTIVES: To investigate whether higher circulating
levels of C-reactive protein (CRP), interleukin-6 (IL-6), and
a1-antichymotrypsin (ACT) are associated with worse cog-
nitive function and decline in old age.
DESIGN: Two independent population-based cohort stud-
ies.
SETTING: The Rotterdam Study (mean follow-up 4.6
years) and the Leiden 85-plus Study (maximal follow-up 5
years).
PARTICIPANTS: Three thousand eight hundred seventy-
four individuals, mean age 72, from the Rotterdam Study,
and 491 individuals, all aged 85, from the Leiden 85-plus
Study.
MEASUREMENTS: Both studies assessed global cogni-
tion, executive function, and memory. Linear regression
analyses were used in the current study to investigate the
associations between inflammatory markers and cognitive
function and decline.
RESULTS: In the Rotterdam Study, higher levels of CRP
and IL-6 were cross-sectionally associated with worse
global cognition and executive function (Po.05). ACT
was not associated with cognitive function. In the Leiden
85-plus Study, estimates were similar for CRP, although not
statistically significant. Higher IL-6 levels were related to a
steeper annual decline in memory function in the longitu-
dinal analysis in the Leiden 85-plus Study (Po.05). The
effect of higher IL-6 levels on global and memory function
decline was stronger in apolipoprotein E (APOE) e4 carriers
(P-interaction5 .01) than in those who were not (P-inter-
action5 .05). In the Rotterdam Study, higher IL-6 levels
were related to a steeper annual decline in global cognition
in APOE e4 carriers only.
CONCLUSION: Systemic markers of inflammation are
only moderately associated with cognitive function and de-
cline and tend to be stronger in carriers of the APOE e4
allele. Systemic markers of inflammation are not suitable
for risk stratification. J Am Geriatr Soc 55:708–716, 2007.
Key words: C-reactive protein; interleukin-6; a1-anti-
chymotrypsin; cognitive decline; atherosclerosis; APOE
e4
Several lines of investigation have suggested that inflam-mation is involved in the pathogenesis of dementia. An-
imal models expressing high levels of proinflammatory
cytokines in the brain suffer from neurodegeneration,1
whereas upregulation of proinflammatory cytokines in tis-
sue cultures leads to microglial activation and neuronal
damage.2 Furthermore, markers of inflammation are found
in and around plaques in the brain,3 and several population-
based studies have shown an association between plasma
levels of inflammatory markers and the risk of dementia.4,5
However, dementia develops over a long preclinical period,
and its association with inflammatory markers may reflect a
consequence of the disease process rather than a causal as-
sociation. In addition, elderly individuals with cognitive
dysfunction often have comorbidities, which might underlie
their elevated inflammatory markers. Therefore, it is im-
portant to investigate the role of inflammatory markers in
the early stages of the disease process, where there is cog-
nitive decline but no full-blown clinical dementia syn-
drome.
Several studies have reported an association between
inflammatory markers and cognitive decline, but these
studies were small,6–8 had a short follow-up,6,9 included
only one marker of inflammation,7 and typically did not
include substantial numbers of individuals aged 80 and
older. Moreover, these studies, except for one,6 did not ac-
count for the possible interrelationships between inflam-
matory markers, atherosclerosis, and cognitive decline.
Many elderly individuals have atherosclerosis, which is a
Address correspondence to M.T. Schram, Department of Gerontology and
Geriatrics C-02-R, Leiden UniversityMedical Center, PO Box 9600, 2300 RC
Leiden, the Netherlands. E-mail: m.vanmeeteren@lumc.nl
DOI: 10.1111/j.1532-5415.2007.01159.x
From the Department of Gerontology and Geriatrics, Leiden University
Medical Center, Leiden, the Netherlands;wDepartment of Epidemiology &
Biostatistics, Erasmus MC, Rotterdam, the Netherlands; and zDepartment of
Psychiatry and Neuropsychology, Maastricht University, Maastricht, the
Netherlands.
JAGS 55:708–716, 2007
r 2007, Copyright the Authors
Journal compilation r 2007, The American Geriatrics Society 0002-8614/07/$15.00
strong risk factor for the development of cognitive decline10
and is strongly related to inflammatory markers such as
C-reactive protein (CRP).11 Therefore, the observed asso-
ciations between inflammatory markers and cognitive de-
cline may be nonspecific (i.e., due to the presence of
atherosclerosis).
In view of these considerations, the hypothesis that
higher levels of the inflammatory markers CRP, interleukin-
6 (IL-6), and a1-antichymotrypsin (ACT) are associated
with cognitive decline, and that atherosclerosis mediates
this association was investigated in two large prospective
population-based studies, the Rotterdam Study and the
Leiden 85-plus Study. Both studies used a dedicated neu-
ropsychological test battery to assess cognitive decline. Be-
cause the apolipoprotein E (APOE) e4 allele is an important
risk factor for cognitive decline,12,13 which may assert its
effects via inflammatory mechanisms, the effect of whether
an individual carries the APOE e4 allele on the association
between inflammatory markers and cognitive decline was
also investigated.
METHODS
Population
Rotterdam Study
The Rotterdam Study is a large, prospective, population-
based cohort study in which all inhabitants aged 55 and
older in Ommoord, a district of Rotterdam, the Nether-
lands, were invited to participate.14 The medical ethics
committee of Erasmus University of Rotterdam approved
the study, and informed consent was obtained from all par-
ticipants. A total of 7,983 individuals (response rate 78%)
participated in the baseline examinations between 1989
and 1993 (mean age 71  25, range 55–106). All individ-
uals were interviewed at home and invited to visit the re-
search center for further examinations. In the third (1997–
99) and fourth surveys (2001–04), cognitive function was
assessed at the research center using a dedicated neuropsy-
chological test battery.
Source Population
The current analyses on inflammation and cognition were
conducted on participants who underwent the neuropsy-
chological test battery and had blood drawn at the third
survey, in which 4,797 individuals participated, of whom
4,206 underwent neuropsychological testing. Blood sam-
ples were obtained from 3,993 of these individuals. Indi-
viduals with dementia (n5119) were excluded, resulting in
3,874 individuals available for analyses.
Of these 3,874 individuals, 2,433 completed the neu-
ropsychological test battery at the fourth survey and thus
were available for longitudinal analyses. Of the 1,441 in-
dividuals who did not participate, 444 had died, 396 had
incomplete data on cognitive function tests, 297 refused to
participate, 193 were too ill to visit the research center, and
111 could not be contacted.
Additional Measurements
Education was measured at the baseline examination
(1989–93) and dichotomized into at more or less than 6
years of schooling. The following measures were all as-
sessed at the third survey (1997–99). Depressive symptoms
were assessed during the home interview, using a depression
questionnaire (the 20-item version of the Center for Epide-
miologic Studies Depression Scale). The use of cardiovas-
cular or antiinflammatory drugs was assessed by
questionnaire during the home interview. The presence of
cardiovascular disease (CVD) was defined as a positive his-
tory of myocardial infarction, percutaneous transluminal
coronary angioplasty, coronary artery bypass graft, stroke,
or the presence of angina pectoris or intermittent claudica-
tion as assessed using the Rose questionnaire. Furthermore,
carotid intima medial thickness greater than 1.0mm and
the presence of plaques in the carotid arteries, as assessed
using ultrasonography,15 were used as measures of athero-
sclerosis. APOE genotypes were assessed as previously de-
scribed16 and were available in 3,664 of the 3,874
individuals.
The diagnosis of dementia was made following a three-
step protocol.17 In short, two brief cognition tests (Mini-
Mental State Examination (MMSE)18 and Geriatric Mental
State schedule (GMS))19 were used to screen all subjects.
If persons screened positive (MMSE score o26 or GMS
organic level40), a physician examined them using the
Cambridge Examination for Mental Disorders of the Eld-
erly and obtained an interview with an informant.20 A
neuropsychologist examined subjects who were suspected
of having dementia if additional neuropsychological testing
was required for diagnosis. An adjudication panel made
final diagnoses.
Leiden 85-plus Study
The Leiden 85-plus Study is a prospective population-based
cohort study of inhabitants of Leiden, the Netherlands. The
medical ethical committee of the Leiden University Medical
Center approved the study, and informed consent was ob-
tained from all participants. Between September 1997 and
September 1999, all inhabitants of Leiden born between
1912 and 1914 (n5705) were contacted within a month
after their 85th birthday. A total of 599 individuals (re-
sponse rate 87%) agreed to participate. From age 85 to 90,
annual neuropsychological tests were performed during
home visits.
Source Population
The current analyses on inflammation and cognition were
conducted on participants who underwent the neuropsy-
chological test battery and had blood samples drawn at age
85. Five hundred ninety-nine individuals underwent neu-
ropsychological testing, of whom 563 had blood samples
taken, 29 refused, and seven died before blood samples
could be taken. Individuals with dementia at age 85, as
defined according to a clinical diagnosis of the treating
physician (n572), were excluded, resulting in 491 indi-
viduals available for analyses.
Data on cognitive function with at least one follow-up
collection were available in 440 individuals. At age 86,
cognitive function was assessed in 437 individuals; at age
87, in 392 individuals; at age 88, in 374 individuals; at age
89, in 299 individuals; and at age 90, in 255 individuals. Of
the remaining 51 individuals without follow-up, 35 died
before the age of 86, 13 refused to participate, and three had
no data on cognitive function tests at follow-up visits.
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Additional Measurements
The following measures were assessed at age 85. Education
was dichotomized into more or less than 6 years of school-
ing. Depressive symptoms were assessed using the 15-item
Geriatric Depression Scale21 during the home interview.
The use of cardiovascular or antiinflammatory drugs was
determined according to pharmacy records. The presence of
CVD was defined as a positive medical history of myocar-
dial infarction, arterial surgery, stroke, angina pectoris, or
intermittent claudication. APOE genotypes were assessed as
previously described22 and were available in 479 of the 491
individuals.
Cognitive Function
Global cognitive function was measured using the MMSE
in both cohorts. In addition, a neuropsychological test bat-
tery was used to assess global cognitive function, executive
function, and memory function. The test battery included
the abbreviated Stroop test part 3 and the Letter Digit
Substitution Task in both cohorts.23
In the Rotterdam Study, word fluency24 was addition-
ally assessed. Because no separate test was administered at
the third survey to measure memory function, the items
from the MMSE and GMS (an organic level test)25 that
assess memory were used. The resulting memory score had
a range of 0 (worst score) to 4 points (best score).
In the Leiden 85-plus Study, memory function (imme-
diate and delayed recall) was assessed using the 12-Picture
Learning Test.26
Compound cognitive test scores were constructed by
transforming individual test scores into standardized
Z-scores (Z-score5 (individual score–mean population
score)/standard deviation of the population score). Com-
pound scores were estimated for global cognitive function
and executive function. In the Rotterdam Study, global
cognitive function was calculated by averaging the Z-scores
of the Stroop test, the Letter Digit Substitution Task,
the word fluency test, and the memory score; in the Leiden
85-plus Study, global cognitive function was calculated by
averaging the Z-scores of the Stroop test, the Letter Digit
Substitution Task, and the 12-Picture Learning Test imme-
diate and delayed recall. Executive function included the
Z-scores of the Stroop test and the Letter Digit Substitution
Task in both cohorts.27
Inflammatory Markers
High-sensitivity CRP was measured using a Rate Near In-
frared Particle Immunoassay (IMMAGE, Immunochemis-
try System, Beckman Coulter, San Diego, CA, detection
limit 0.2mg/L, coefficient of variation (CV) 3.2%) in the
Rotterdam Study. CRP was measured using a fully auto-
mated Hitachi 747 system (Hitachi, Tokyo, Japan, detec-
tion limit 1mg/L, CVo5%) in the Leiden 85-plus Study.
IL-6 plasma levels were determined using a quantitative
enzyme-linked immunosorbent assay (ELISA) technique
(Quantikine HS IL-6 kit, R&D Systems, Oxon, UK, detec-
tion limit 0.094 pg/mL, CV 8.7%) and ACT plasma levels
using kinetic nephelometry (Behring Nephelometer BN200,
Marburg, Germany, detection limit 1.5mg/dL, CV 2.8%) in
a random sample of the Rotterdam Study (n5491). IL-6
levels in the Leiden 85-plus Study were obtained from an ex
vivo whole blood stimulation assay at age 85.28 In short,
after incubation of venous blood samples at 371C and 5%
carbon dioxide for 24 hours, supernatants were collected
and stored at  801C until IL-6 was measured using a
standard ELISA (Sanquin, Amsterdam, the Netherlands,
detection limit 4 pg/mL, CV 5–10%). Unstimulated IL-6
levels were used as an estimate of circulating IL-6 levels. In
addition, circulating IL-6 levels were measured at age 86
using the same ELISA.
Statistical Analyses
First, the cross-sectional association between systemic
markers of inflammation and cognitive function was inves-
tigated using linear regression analyses and markers of in-
flammation both in categories and as continuous variables
in the models. CRP and IL-6 were log-transformed because
of their skewed distribution.
Second, linear regression was used to investigate the
longitudinal association between systemic markers of in-
flammation and cognitive decline, with the annual change
in cognitive function as the dependent variable and inflam-
matory markers as the independent variable. In the Rotter-
dam Study, annual cognitive decline was calculated as the
difference between the test scores at the fourth and the third
survey divided by follow-up time (mean follow-up
4.6  0.5 years). In the Leiden 85-plus Study, annual cog-
nitive decline was calculated by subtracting test scores at
the latest follow-up examination from the test scores at age
85 and dividing them by the follow-up time (mean follow-
up 3.4  1.8 years).
All analyses were adjusted for age (Rotterdam Study
only), sex, and education level, because these factors
strongly relate to cognitive function. On further analysis,
body mass index, diabetes mellitus, and prevalent CVD
were adjusted for. Finally, whether the association between
inflammatory markers and cognitive decline is different in
the presence of APOE e4, CVD, and atherosclerosis was
tested for.
RESULTS
Table 1 gives principal features of both study populations.
Table 2 shows the clinical characteristics of both study
samples used for cross-sectional and longitudinal analyses.
In the sample from the Rotterdam Study, mean age was
72.1, 58% were women, and 29% had primary education
only. In the Leiden 85-plus Study, mean age was 85, 65%
were women, and 62% had primary education only. Cog-
nitive function in the Rotterdam Study was better than in
the Leiden 85-plus Study, reflecting the younger age range
and higher education level in the Rotterdam Study.
As expected, participants who were included in the
follow-up examinations of the Rotterdam Study were
younger and had better cognitive function than the com-
plete sample. Median follow-up was 4.6 years (range 1.5–
7.1). In the Leiden 85-plus Study, individuals with at least 1
year of follow-up had only slightly better cognitive function
than the complete sample. Median follow-up was 5.0 years
(range 1.0–5.0).
710 SCHRAM ET AL. MAY 2007–VOL. 55, NO. 5 JAGS
Inflammatory Markers and Cognitive Function
In the Rotterdam Study, higher CRP and IL-6 levels were
associated with worse cognitive function (Table 3). Esti-
mates were similar in the Leiden 85-plus Study for CRP,
although not statistically significant (Table 3). ACTwas not
related to cognitive function (all P4.37).
Additionally, the study populations were stratified for
the presence or absence of an APOE e4 allele and according
to the presence or absence of CVD or atherosclerosis at
baseline. The association between inflammatory markers
and cognitive function did not differ between those with
and without an APOE e4 allele or between those with or
without CVD or atherosclerosis. This held true for both
cohorts (data not shown).
Inflammatory Makers and Cognitive Decline
Table 4 shows the association between CRP and IL-6 and
cognitive decline, as measured during follow-up. In both
cohorts, nearly all point estimates of cognitive function
were negative, indicating worse outcome, when levels of
inflammatory markers at baseline were higher. There may
be a significant association between IL-6 and memory de-
cline in the Leiden 85-plus Study. Higher levels of ACTwere
not related to a steeper annual cognitive decline (all
P4.19).
Table 5 shows the associations between inflammatory
markers and cognitive decline stratified for carriers and
noncarriers of the APOE e4 allele. In the Rotterdam Study,
IL-6 was associated with a decline in global cognitive func-
tion in those who carry the APOE e4 allele but not in those
who do not. In the Leiden 85-plus Study, the associations of
CRP and IL-6 with global cognitive decline and memory
decline were stronger in carriers of the APOE e4 allele
than in noncarriers (P-interaction o .05). ACT was asso-
ciated with a decline in executive function in APOE e4 car-
riers (annual decline –0.020, 95% confidence interval
(CI)5 –0.039 to –0.002), but not in noncarriers (annual
decline –0.001 95% CI5 –0.017–0.019), P-inter-
action5 .15).
The presence of CVD or atherosclerosis at baseline did
not consistently influence the relationship between inflam-
matory markers and cognitive decline in either of the two
cohorts (data not shown).
Additional Analyses
Additional adjustment for symptoms of depression, use of
antiinflammatory drugs, body mass index, CVD, and dia-
betes mellitus did not materially change the results (data not
shown). Furthermore, in the Rotterdam sample, whether
the association between inflammatory markers and cogni-
tive function and decline was stronger at old age was in-
vestigated; no consistent influence of age on this association
was found.
In this follow-up study on inflammation contributing to
cognitive decline, those who suffered from dementia at
baseline were excluded (Rotterdam Study: n5119, Leiden
85-plus Study: n572), but when individuals with dementia
at baseline were reintroduced into the analyses, the results
did not materially change (data not shown).
In addition to unstimulated production levels of IL-6,
circulating IL-6 was also measured at age 86 in the Leiden
85-plus Study (n5427). In this sample, all analyses of the
relationship between cognitive function and decline and
circulating IL-6 were repeated. The key question was
whether the association between higher unstimulated IL-6
production levels and greater annual cognitive decline could
Table 1. Overview of Both Study Populations
Characteristics Rotterdam Study Leiden 85-plus Study
Baseline investigation 1989–1993 1997–1999
Inclusion All individuals aged 55 living in
Ommoord, a district of Rotterdam
All individuals born between 1912 and
1914 living in Leiden
Age at baseline 55 (range 55–99) 85
Cognitive function
Measurements Mini-Mental State Examination Mini-Mental State Examination
Stroop test Stroop test
Letter Digit Substitution Task Letter Digit Substitution Task
Memory score
Word Fluency
Immediate and delayed recall of the 12-Picture
Learning Test
Number of measurements Two Annual (maximum 5)
Measurements used Third survey (1997–1999) Baseline (1997–1999)
Fourth survey (2001–2004) Latest follow-up examination
Follow-up 4.6 years Maximum 5 years
Markers of inflammation
Measurements High-sensitivity CRP CRP
IL-6 Unstimulated IL-6
ACT
Measured at: Third survey (1997–1999) Baseline
Number 3874 for high-sensitivity CRP
491 for IL-6/ACT
491 for CRP
491 for unstimulated IL-6
CRP5C-reactive protein; IL-65 interleukin-6; ACT5 a1-antichymotrypsin.
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Table 2. Characteristics at the Third Survey of the Rotterdam Study and at Age 85 of the Leiden 85-plus Study
Characteristics
Rotterdam Study Leiden 85-plus Study
Study Sample
at Third Survey
Study Sample
at Third Survey
with 4.6-Year
Follow-Up
Study Sample
at Baseline
Study Sample at
Baseline with at
Least 1-Year
Follow-Up
(n5 3,874) (n5 2,433) (n5 491) (n5 440)
Clinical characteristics
Age, mean  SD 72.1  6.9 70.2  5.7 85 85
Female, % 58 58 65 67
Low level of education, % 29 26 62 60
Cardiovascular disease, % 37 31 62 61
Stroke, % 5 3 9 8
Present smoking, % 18 17 15 14
Diabetes mellitus, % 12 10 16 16
Medication use
Use of cardiovascular drugs, % 48 45 53 52
Use of nonsteroidal
antiinflammatory drugs, %
8 8 28 27
Cognitive function
MMSE score, mean  SD 27.7  2.0 28.1  1.6 25.4  4.6 25.5  4.4
Center for Epidemiological
Studies Depression Scale score,
median (interquartile range)
1 (0–6) 1 (0–5) F F
Geriatric Depression Scale score,
median (interquartile range)
F F 2 (1–3) 2 (1–3)
Stroop Test Part 3, seconds,
mean  SD
57.5  21.6 53.6  17.6 81.5  32.9 81.1  33.3
Letter Digit Substitution Task,
correct answers, mean  SD
26.6  7.1 28.1  6.5 17.3  7.0 17.6  7.0
Word Fluency, words, mean  SD 20.9  5.5 21.8  5.3 F F
Memory Score delayed recall,
words, mean  SD
3.2  0.9 3.3  0.8 F F
12-Picture Learning Test
immediate recall, total pictures of
3 trials, mean  SD
F F 24.4  5.4 24.4  5.5
12-Picture Learning Test delayed
recall, pictures, mean  SD
F F 8.9  2.5 8.9  2.5
Inflammatory markers
High-sensitivity CRP, mg/L,
median (interquartile range)
2.4 (1.2–4.6) 2.2 (1.1–4.2) F F
CRP, mg/L, median
(interquartile range)
F F 4 (1–8) 3 (1–7)
IL-6, pg/mL, median
(interquartile range)
2.11 (1.44–3.32) 1.96 (1.37–2.88)w F F
Unstimulated IL-6, pg/mL, median
(interquartile range)
F F 11 (0–53) 10 (0–57)
ACT, mg/dL, mean  SD 39.8  11.3 38.9  10.8w F F
Note: Results in the Rotterdam Study for neuropsychological tests and C-reactive protein (CRP) were available in 3,874 individuals for the Mini-Mental State
Examination (MMSE), 3,720 for the Stroop Test, 3,766 for the Letter Digit Substitution Task, 3,802 forWord Fluency, and 3,871 for theMemory Score delayed recall.
Results for neuropsychological tests, interleukin-6 (IL-6) and a1-antichymotrypsin (ACT) were available in 491 individuals for the MMSE, 487 for the Stroop Test,
489 for the Letter Digit Substitution Task, 487 for Word Fluency, and 491 for the Memory Score delayed recall. Results in the Leiden 85-plus Study for neu-
ropsychological tests and inflammatory markers were available in 491 individuals for MMSE, 413 for the Stroop test, 408 for the Letter Digit Substitution Task, and
426 and 425 for immediate and delayed recall, respectively, of the 12-Picture Learning Test.
 In a random sample of 491.
w In a sample of 300.
SD5 standard deviation.
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be replicated, especially in the memory domain. High circu-
lating IL-6 levels were associated with an annual decline in
MMSE of –0.418 points (95% CI5 –0.829 to –0.133) and
with an annual decline in memory function of –0.254 words
(95% CI5 –0.488 to –0.019). Corresponding estimates
for unstimulated IL-6 levels were –0.352 points (95%
CI5 –0.756–0.061) for the MMSE and –0.334 words
(95% CI5 –0.588 to –0.080) for memory decline. The
similar effect sizes suggest that the unstimulated production
level of IL-6 in whole blood samples is a valid estimate of
circulating IL-6.
DISCUSSION
In this study, systemic levels of CRP and IL-6 were only
moderately associated with estimates of global cognition
and executive function in cross-sectional analyses. Systemic
levels of IL-6 were related to a longitudinal decline in
memory function in the Leiden 85-plus Study only. In
APOE e4 carriers, greater IL-6 levels tended to be more
strongly associated with the annual decline in global cog-
nition and memory function than in noncarriers, although
because of the large number of comparisons made and the
large sample size, these results may be due to chance.
Table 3. Association Between Inflammatory Markers and Cognitive Test Performance
Inflammatory Marker
Rotterdam Study Leiden 85-plus Study
Difference in Test
Performance
(95% CI) R R2 P-value
Difference in Test
Performance
(95% CI) R R2 P-value
CRP per SD (n5 3,874) (n5 491)
MMSE score  0.04 ( 0.10–0.02) 0.38 0.14 .15  0.14 ( 0.52–0.23) 0.32 0.10 .46
Global cognitive
function (Z-score)
 0.03 ( 0.05 to–0.02) 0.53 0.29 o.001  0.05 ( 0.11–0.02) 0.30 0.09 .20
Executive function (Z-score)  0.04 ( 0.07 to–0.02) 0.54 0.29 o.001  0.05 ( 0.13–0.03) 0.40 0.16 .23
Memory (delayed recall)  0.03 ( 0.05–0.001) 0.29 0.09 .06  0.15 ( 0.39–0.09) 0.13 0.02 .21
Interleukin-6 per SD (n5 491) (n5 491)
MMSE score  0.22 ( 0.41 to  0.03) 0.38 0.15 .03 0.16 ( 0.22–0.53) 0.32 0.10 .41
Global cognitive
function (Z-score)
 0.08 ( 0.14 to  0.02) 0.56 0.31 .009 0.01 ( 0.06–0.07) 0.29 0.09 .89
Executive function (Z-score)  0.10 ( 0.17 to  0.03) 0.54 0.30 .008 0.02 ( 0.06–0.09) 0.40 0.16 .66
Memory (delayed recall)  0.05 ( 0.14–0.04) 0.31 0.10 .27 0.01 ( 0.22–0.25) 0.11 0.01 .92
Note: All analyses were performed using linear regression adjusted for age (Rotterdam Study only), sex, and education.
Measured as high-sensitivity C- reactive protein (CRP) in the Rotterdam Study and as CRP in the Leiden 85-plus Study.
CI5 confidence interval; SD5 standard deviation; MMSE5Mini-Mental State Examination.
Table 4. Association Between Inflammatory Markers and Annual Cognitive Decline
Inflammatory Marker
Rotterdam Study Leiden 85-plus Study
Annual Decline
(95% CI) R R2 P-value
Annual Decline
(95% CI) R R2 P-value
CRP per SDw (n5 2,433) (n5 440)
MMSE score 0.001 ( 0.016–0.019) 0.14 0.02 .88  0.100 ( 0.290–0.090) 0.07 0.01 .30
Global cognitive
function (Z-score)
 0.002 ( 0.006–0.002) 0.18 0.03 .43  0.005 ( 0.032–0.021) 0.03 0.00 .69
Executive function (Z-score)  0.003 ( 0.007–0.002) 0.22 0.05 .21  0.020 ( 0.055–0.014) 0.13 0.02 .24
Memory (delayed recall) 0.002 ( 0.006–0.011) 0.06 0.00 .59  0.020 ( 0.137–0.097) 0.10 0.01 .74
Interleukin-6 per SD (n5 304) (n5 440)
MMSE score  0.035 ( 0.087–0.020) 0.19 0.04 .22  0.133 ( 0.317–0.050) 0.08 0.01 .15
Global cognitive
function (Z-score)
 0.008 ( 0.021–0.006) 0.14 0.03 .26  0.024 ( 0.049–0.001) 0.11 0.01 .06
Executive function (Z-score)  0.005 ( 0.019–0.009) 0.24 0.06 .49  0.011 ( 0.043–0.022) 0.12 0.02 .52
Memory (delayed recall)  0.008 ( 0.038–0.022) 0.08 0.01 .60  0.123 ( 0.233 to  0.013) 0.15 0.02 .03
Note: All analyses were performed using linear regression, adjusted for age (Rotterdam Study only), sex, and education level. In the Leiden 85-plus Study follow-up,
data on cognitive function were available in 440 individuals for Mini-Mental State Examination (MMSE), 350 for global cognitive function, 328 for executive
function, and 368 for memory.
Estimates from a mean follow-up of 5 years.
wMeasured as high-sensitivity C- reactive protein (CRP) in the Rotterdam Study and as CRP in the Leiden 85-plus Study.
CI5 confidence interval; SD5 standard deviation.
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Previous studies also demonstrated minor associations
between inflammatory markers and cognitive decline,6–9,29
although the effect size being modest does not imply that
the involvement of systemic inflammation in the patho-
physiology of cognitive decline is modest as well.30 In fact,
the consistent finding of this association in different pop-
ulations may suggest that inflammation is involved in the
pathophysiology of cognitive decline, although the possi-
bility that both inflammatory activation and cognitive de-
cline reflect the consequence of an underlying common
disease process cannot be excluded. In contrast, these find-
ings imply that measurement of inflammatory markers is
not suitable for risk prediction of cognitive decline in clin-
ical practice.
Dementia, the end stage of severe cognitive decline,
develops over a long preclinical period. Therefore, its as-
sociation with inflammatory markers may reflect a conse-
quence of the disease process rather than a causal path. This
may play a role in cross-sectional studies and in studies with
a short follow-up. To limit the possibility that individuals
with dementia would affect the association between in-
flammatory markers and cognition, subjects with dementia
were vigorously excluded from the analyses. It cannot be
excluded that subjects who are early in the dementia proc-
ess and do not fulfill the criteria for dementia yet affect the
associations as described here, although when the analyses
were repeated, and those with dementia at baseline were
included, the observed associations did not change. It was
previously demonstrated in the Rotterdam Study that ACT
was strongly related to incident dementia, whereas CRP
and IL-6 were only moderately associated with dementia.5
The discrepancy with the current findings suggests that
timing is important in the association between inflamma-
tory markers and cognitive decline and dementia. It is pos-
sible that inflammation can only predict the late stages of
cognitive decline, that of dementia, whereas it is not suit-
able for risk stratification of early cognitive decline.
A trend toward a stronger association between inflam-
matory markers and cognitive decline in carriers of the
APOE e4 allele was found. This is in agreement with a
previous finding that the APOE e4 allele is associated with
an impaired response to cerebral damage,31 which may lead
to a steeper decline in cognitive function, although signif-
icant interactions were observed only in the Leiden 85-plus
sample, which may imply an important influence of age on
the relationship between inflammatory markers and cogni-
tive decline. However, formal testing of this suggestion did
not demonstrate a stronger association between inflamma-
tory markers and cognitive decline in old age. Previously,
the Longitudinal Aging Study Amsterdam investigated
whether APOE e4 modulates the association between in-
flammatory markers and cognitive decline6 and did not find
an interaction between APOE e4, inflammatory markers,
and cognitive decline. Taken together, the effect of the
APOE e4 allele on the relationship between inflammation
and cognition needs further investigation.
No interaction was observed between atherosclerosis
or CVD and the association between inflammatory markers
and cognitive function and decline. This is in contrast
to previous results from the Leiden 85-plus Study,
which showed that inflammatory markers interact with
atherosclerosis in their association with cognitive decline.32T
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However, these results were derived from cross-sectional
data and are therefore more difficult to interpret with re-
spect to causality.
The current study had several strengths. First, data on
inflammation and cognitive function were available in a
large population-based sample of 3,874 individuals from
the Rotterdam Study over 4.6 years of follow-up and of 491
individuals of the Leiden 85-plus Study with annual follow-
up measures over a period of 5 years. Second, cognitive
function was measured using a neuropsychological test
battery that measures separate cognitive domainsFexecu-
tive and memory function, as well as global functionFand
used cognitive decline as an early indicator of the dementia
process. Third, by combining data from two population-
based studies with a different age range, it can be concluded
that the association between inflammatory markers and
cognition is present over a large age range.
This study had also several limitations. First, plasma
levels of CRP, IL-6, and ACT were measured only once,
which may have diluted the associations found and
may thus have led to an underestimation of the risk
estimates. Second, different assays were used to determine
CRP levels. The discriminative power of the Rotterdam
Study for the analyses including CRP was larger because of
the sample size and the use of a high-sensitivity CRP assay.
This may explain why significant findings could not be
replicated in both study samples. Third, in the Leiden
85-plus Study, unstimulated IL-6 production in a whole
blood assay was used as an estimate of circulating plasma
IL-6 levels. Although these production levels are higher
than circulating plasma levels, this has been demonstrated
to be a good estimate of plasma IL-6 levels. Fourth, a
number of statistical analyses were performed, which
carries the possibility of significant findings by chance
(i.e., caused by random type 2 errors produced by the large
sample size and number of statistical test performed).
Although, the main interest was to replicate the findings
in two independent populations, which automatically
doubled the number of analyses performed, and the
analyses were based on an a priori hypotheses, a stricter
P-value, for instance of o.01, might have been more
appropriate to use for these analyses. With this stricter
interpretation, statistical significance in the prospective
analyses would have been lost.
Although the cohorts were population based and pro-
spectively followed, selection bias may have occurred by
selective nonresponse. The participation rate was probably
lowest in subjects with cognitive impairment. Individuals
with follow-up data had a better cognitive performance
than those who did not return for follow-up examinations,
especially in the Rotterdam Study. This suggests that the
observed cognitive decline is probably lower than the actual
decline and therefore that the associations with the inflam-
matory markers may have been underestimated.
In conclusion, systemic markers of inflammation are
only moderately associated with cognitive function and de-
cline. These data show some suggestion that these associ-
ations may be stronger in the presence of the APOE e4
allele, although these results should be interpreted with care
and may be due to chance. Systemic markers of inflamma-
tion are not suitable to predict individual risk of cognitive
decline.
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